https://mavenbio.com/products https://mavenbio.com/intelligence https://mavenbio.com/products/research-agent https://mavenbio.com/products/smart-tables https://mavenbio.com/products/document-grids https://mavenbio.com/products/report-builder https://mavenbio.com/products/workflows https://mavenbio.com/integrations https://mavenbio.com/integrations/mcp https://mavenbio.com/integrations/claude-plugin https://mavenbio.com/integrations/api https://mavenbio.com/solutions https://mavenbio.com/solutions/pharma-biotech https://mavenbio.com/solutions/consultants https://mavenbio.com/solutions/investment-firms https://mavenbio.com/ https://mavenbio.com/about https://mavenbio.com/pricing https://mavenbio.com/security https://mavenbio.com/resources/faq https://mavenbio.com/research https://mavenbio.com/contact https://mavenbio.com/privacy https://mavenbio.com/terms https://mavenbio.com/mcp/privacy https://mavenbio.com/research/top-10-biopharma-market-cap-gains-september-2023-vs-2024 2024-09-25T16:53:35Z https://mavenbio.com/research/top-10-pharma-companies-by-revenue 2024-05-03T19:56:38Z https://mavenbio.com/research/ira-s-first-10-how-much-revenue-is-at-stake 2024-08-21T15:10:18Z https://mavenbio.com/research/radiopharmaceutical-deals-recap 2024-07-15T16:42:44Z https://mavenbio.com/research/the-best-selling-neurology-drugs-in-q3_2025-where-multibillion-dollar-franchises-are-taking 2025-12-24T20:29:12Z https://mavenbio.com/research/big-pharma-m-and-a-in-2025-a-shift-toward-derisked-growth 2026-01-08T15:00:57Z https://mavenbio.com/research/bms-top-10-medicines-by-sales-in-q2-24 2024-08-02T17:23:39Z https://mavenbio.com/research/advancing-beyond-statins-the-landscape-of-emerging-cholesterol-lowering-medicines 2025-12-07T12:22:56Z https://mavenbio.com/research/glp-1-small-molecule 2024-07-18T20:18:33Z https://mavenbio.com/research/gilead-q2-2025-earnings-hiv-trodelvy 2025-08-15T14:55:44Z https://mavenbio.com/research/crowning-achievements-recent-royalty-deals-in-biopharma 2024-09-03T17:03:02Z https://mavenbio.com/research/inside-big-pharma-s-portfolios-what-drove-q3-2025-revenue 2025-12-15T22:10:38Z https://mavenbio.com/research/abbvie-q2-earnings-immunology-strength-overshadows-aesthetics-challenges 2024-07-29T11:25:49Z https://mavenbio.com/research/bladder-cancer-emerging-therapies-and-key-areas-to-watch 2025-04-06T00:27:07Z https://mavenbio.com/research/biopharma-s-direct-to-consumer-evolution 2024-09-03T16:39:36Z https://mavenbio.com/research/top-10-biopharma-deals-q1-2024 2024-04-23T17:55:51Z https://mavenbio.com/research/shifts-in-pharma-revenue-mix-across-leading-portfolios-2019-2024 2026-02-02T15:22:11Z https://mavenbio.com/research/beyond-insulin-emerging-disease-modifying-therapies-in-type-1-diabetes-Mellitus 2025-12-29T19:31:59Z https://mavenbio.com/research/top-10-biopharma-companies-by-revenue-q2-2024 2024-08-29T17:07:58Z https://mavenbio.com/research/astrazeneca-q2-24-earnings-recap 2024-08-12T15:04:03Z https://mavenbio.com/research/top-10-medicines-by-q2-2024-sales 2024-08-21T15:29:41Z https://mavenbio.com/research/top-15-drugs-by-sales-in-2023 2024-03-22T21:04:36Z https://mavenbio.com/research/novartis-navigates-patent-cliff-with-robust-pipeline-and-strategic-focus 2024-06-25T18:52:50Z https://mavenbio.com/research/top-10-biopharma-companies-by-q2-2024-sales 2024-09-11T16:16:26Z https://mavenbio.com/research/notable-biopharma-fundraises-in-august 2024-09-09T21:27:41Z https://mavenbio.com/research/emerging-cholesterol-lowering-therapies 2025-12-17T23:46:29Z https://mavenbio.com/research/clinical-stage-kras-therapeutics-how-g12d-and-pan-kras-strategies-are-reshaping-drug-development 2026-01-26T14:43:23Z https://mavenbio.com/research/big-pharma-partnerships-in-2023-a-comprehensive-overview 2024-01-19T20:35:10Z https://mavenbio.com/research/biopharma-launch-activity-new-molecular-and-biologic-entities-2021-2025 2026-01-16T14:01:05Z https://mavenbio.com/research/biotech-ipo-trifecta 2024-09-23T20:00:20Z https://mavenbio.com/research/her2-targeted-therapies-solid-tumors 2025-12-17T17:49:31Z https://mavenbio.com/research/fda-drug-approvals-in-2025-what-the-year-s-46-new-therapies-reveal-about-industry-direction 2026-01-13T14:35:46Z https://mavenbio.com/research/biotech-funding-valuation-shifts-from-seed-to-ipo 2024-09-25T17:24:33Z https://mavenbio.com/research/which-large-pharma-companies-spend-the-most-on-Mergers 2024-05-07T21:23:54Z https://mavenbio.com/research/the-shifting-spending-priorities-of-big-pharma 2024-07-26T15:34:43Z https://mavenbio.com/research/top-10-biopharma-companies-by-revenue-2003-to-2023 2024-08-01T14:01:36Z https://mavenbio.com/research/top-15-immunology-drugs-by-sales-of-q1-24 2024-07-01T18:39:06Z https://mavenbio.com/research/the-radiopharmaceutical-revolution 2024-09-27T19:40:25Z https://mavenbio.com/research/the-constant-evolution-of-biopharma-a-decade-of-transformation 2024-07-08T14:12:14Z https://mavenbio.com/research/top-10-immunology-drugs-2023 2024-04-13T17:58:54Z https://mavenbio.com/research/pharma-stock-performance-2025-valuation-divide 2025-12-11T15:16:18Z https://mavenbio.com/research/merck-post-keytruda-potential-growth-drivers 2024-09-23T19:24:30Z https://mavenbio.com/research/upcoming-patent-expirations-for-top-15-drugs 2024-04-23T17:59:46Z https://mavenbio.com/research/ai-platforms-for-biotech-and-pharmaceutical-consulting 2025-07-23T17:30:58Z https://mavenbio.com/research/merck-s-usd10b-verona-acquisition-ohtuvayre-leads-next-gen-copd-innovation 2025-07-21T21:11:10Z https://mavenbio.com/research/sanofi-q2-24-earnings-recap 2024-08-12T14:15:30Z https://mavenbio.com/research/j-and-j-s-q2-earnings-and-key-milestones-in-immunology-and-oncology 2024-07-22T14:34:12Z https://mavenbio.com/research/top-15-immunology-medicines-by-q2-2024-sales 2024-08-29T17:16:02Z https://mavenbio.com/research/roche-10-year-sales-evolution 2024-08-21T15:48:47Z https://mavenbio.com/research/lilly-and-novo-how-do-glp-1-sales-compare 2024-08-14T15:39:25Z https://mavenbio.com/research/pfizer-delivers-robust-q2-2024-performance-raises-full-year-guidance 2024-09-11T14:55:07Z https://mavenbio.com/research/abbvie-q3-2025-earnings-skyrizi-rinvoq 2025-12-17T18:48:15Z https://mavenbio.com/research/dato-dxd 2024-09-27T20:07:25Z https://mavenbio.com/research/top-15-oncology-drugs-2023 2024-04-15T18:59:48Z https://mavenbio.com/research/market-capitalization-trends-of-leading-pharmaceutical-companies-in-2025 2025-12-17T18:41:56Z https://mavenbio.com/research/alzheimer-s-disease-landscape 2024-08-15T14:28:30Z https://mavenbio.com/research/how-much-do-large-biopharma-companies-spend-on-capex 2024-08-29T17:22:40Z https://mavenbio.com/research/top-15-oncology-medicines-by-q2-2024-sales 2024-08-29T17:04:26Z https://mavenbio.com/research/the-prize-of-the-eyes-eylea-and-vabysmo 2024-07-23T19:05:02Z https://mavenbio.com/research/top-15-biopharma-companies-by-oncology-sales 2024-05-07T21:15:34Z https://mavenbio.com/research/revolutionizing-cancer-treatment-the-emergence-of-mrna-vaccines 2024-09-04T15:41:04Z https://mavenbio.com/research/ai-tools-for-pharma-market-research 2025-07-15T12:54:24Z https://mavenbio.com/research/pfizer-q3-2025-earnings-portfolio-rebalancing 2025-12-17T18:21:08Z https://mavenbio.com/research/who-will-transform-the-hae-market-Ionis-kalvista 2025-04-06T00:32:59Z https://mavenbio.com/research/top-ai-platforms-for-life-sciences-investment-banking 2025-08-07T20:51:06Z https://mavenbio.com/research/atopic-dermatitis-landscape 2024-08-29T17:26:04Z https://mavenbio.com/research/how-drug-pricing-in-the-us-compares-to-other-countries 2024-01-20T16:19:58Z https://mavenbio.com/research/johnson-and-johnson-q3-2025-earnings-oncology-and-immunology-drive-growth-after-strategic 2025-12-19T18:04:01Z https://mavenbio.com/research/u-s-pharma-manufacturing-and-r-and-d-site-investments-announced-in-2025 2026-01-05T14:02:51Z https://mavenbio.com/research/j-and-j-s-q2-highlights-innovative-medicine-drives-growth-despite-stelara-slowdown 2025-07-31T18:43:54Z https://mavenbio.com/research/ai-platforms-for-biotech-and-pharmaceutical-equity-research 2025-08-01T17:53:32Z https://mavenbio.com/research/top-10-biopharma-fundraises-in-april-2024 2024-05-14T18:14:54Z https://mavenbio.com/research/ai-drug-discovery-partnerships 2024-01-20T16:19:07Z https://mavenbio.com/research/epidemiologies-of-oncology-insights-from-astrazeneca-and-novartis 2024-09-09T14:13:02Z https://mavenbio.com/research/capital-efficiency-in-chinese-biotech-a-comparative-analysis-of-licensing-deal-structures 2026-01-07T22:32:14Z https://mavenbio.com/research/a-new-era-in-duchenne-muscular-dystrophy-diseasemodifying-therapies-in-development 2025-12-26T14:53:53Z https://mavenbio.com/research/moderna-research-and-development-cut 2024-09-20T20:13:30Z https://mavenbio.com/research/select-eli-lilly-u-s-patent-expiries 2024-09-20T20:41:47Z https://mavenbio.com/research/us-biotech-ipos-h1-2025-performance 2025-08-06T19:56:24Z https://mavenbio.com/research/top-pharmaceutical-r-and-d-spending-in-2025-how-big-pharma-is-allocating-capital-through-nine 2025-12-26T16:22:22Z https://mavenbio.com/research/merck-q3-2025-earnings-keytruda-pipeline 2025-12-17T17:33:01Z https://mavenbio.com/research/the-next-generation-of-chronic-spontaneous-urticaria(csu)-treatments-targets-approvals-and-pipeline 2025-12-23T14:18:11Z https://mavenbio.com/research/best-selling-immunology-drugs-in-q3-2025-revenue-leaders-and-market-dynamics 2025-12-30T15:59:54Z https://mavenbio.com/research/inside-big-pharma-portfolios-part2-what-drove-revenue-in-q3-2025 2025-12-22T15:23:03Z https://mavenbio.com/research/new-ema-medicine-approvals-through-august-2024 2024-09-04T16:14:47Z https://mavenbio.com/research/esmo-2024-recap-of-notable-advances-in-oncology 2024-09-23T16:07:06Z https://mavenbio.com/research/roche-pharmaceutical-division-performance-in-q2-yoy 2024-09-11T14:11:55Z https://mavenbio.com/research/15-biggest-biotech-fundraisings-in-q1-2024 2024-05-03T20:01:01Z https://mavenbio.com/research/race-for-glp-1-obesity-drugs-heats-up 2024-01-20T16:21:14Z